Free Trial
NASDAQ:HCWB

HCW Biologics 5/15/2024 Earnings Report

HCW Biologics logo
$4.76 -0.11 (-2.16%)
As of 12:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HCW Biologics EPS Results

Actual EPS
-$8.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

HCW Biologics Revenue Results

Actual Revenue
$1.13 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

HCW Biologics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

HCW Biologics Earnings Headlines

"I'm risking my reputation on this"
Crypto book predicted the last bull run (get it FREE now) This newly updated edition contains everything we've learned from interviewing the biggest names in crypto on our Crypto 101 podcast, which has over 17 million downloads and 600+ episodes. "Crypto Revolution" isn't just another book – it's your roadmap to potentially life-changing wealth in the current crypto bull run
See More HCW Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HCW Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HCW Biologics and other key companies, straight to your email.

About HCW Biologics

HCW Biologics (NASDAQ:HCWB), a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

View HCW Biologics Profile

More Earnings Resources from MarketBeat